Spots Global Cancer Trial Database for Optimizing Abiraterone Therapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Optimizing Abiraterone Therapy
Official Title: Optimizing Abiraterone (Zytiga®) Therapy by Exploring the Relation Between an Early Biomarker - Drug Exposure - as a Predictor for Drug Response in Patients With mCRPC
Study ID: NCT02426333
Interventions
Study Description
Brief Summary: The purpose of this study is to explore whether early abiraterone exposure is related to treatment response in patients with metastatic castration resistant prostate cancer. Furthermore to explore the relation between biomarkers and treatment response and drug exposure.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Jeroen Bosch Ziekenhuis, Den Bosch, , Netherlands
Canisius Wilhelmina Ziekenhuis, Nijmegen, , Netherlands
Radboud UMC, Nijmegen, , Netherlands
Contact Details
Name: Nielka van Erp, PharmD, PhD
Affiliation: Radboud University Medical Center
Role: PRINCIPAL_INVESTIGATOR
Name: Jack Schalken, PhD
Affiliation: Radboud University Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
